<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>General introduction and outline of the thesis</td>
<td>9</td>
</tr>
<tr>
<td>2</td>
<td>Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment and survival in 3,585 patients from 1989-2012</td>
<td>25</td>
</tr>
<tr>
<td>3</td>
<td>The EUTOS population-based registry: incidence and clinical characteristics of 2,904 CML patients in twenty European countries</td>
<td>43</td>
</tr>
<tr>
<td>4</td>
<td>High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group</td>
<td>63</td>
</tr>
<tr>
<td>5</td>
<td>Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial Group for Haemato-Oncology (HOVON)</td>
<td>79</td>
</tr>
<tr>
<td>6</td>
<td>New insights in the pathogenesis of chronic myeloid leukemia: towards a path to cure</td>
<td>93</td>
</tr>
<tr>
<td>7</td>
<td>Leukemic stem cell quantification in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP) predicts response to nilotinib: results from the ENEST1st stem cell substudy</td>
<td>119</td>
</tr>
<tr>
<td>8</td>
<td>Summary and future perspectives</td>
<td>139</td>
</tr>
<tr>
<td>Appendices</td>
<td>Samenvatting voor medisch niet-ingewijden</td>
<td>145</td>
</tr>
<tr>
<td></td>
<td>Curriculum Vitae</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>List of Publications</td>
<td>161</td>
</tr>
<tr>
<td></td>
<td>Dankwoord</td>
<td>167</td>
</tr>
</tbody>
</table>